The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant
Activating mutations in FLT3 in acute myeloid leukemia (AML) portend a poor prognosis, and targeting FLT3 with a tyrosine kinase inhibitor has been an area of intense research recently. Most FLT3 mutated AML patients undergo hematopoietic stem cell transplantation (HSCT) as standard of care but a si...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-01-01
|
| Series: | Leukemia Research Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048918300499 |